Reality Check on G-CSF
Market access for G-CSF treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Increasing percentage of restricted lives across commercial, health exchange and medicare medical benefits
- Class Trends: The role of biosimilars in future G-CSF market access match-ups and prescriber attitudes
- Key Findings: How increasing complexity and variation in PAs and step edits requires a need to normalize data points
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.